In August 2025, Bayer announced a study of researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the ...

And early last month AstraZeneca extended its cardiorenal pipeline with a $1.3 billion acquisition of CinCor Pharma, the $26-per-share upfront deal focusing on baxdrostat (CIN-107), an aldosterone ...